- Home
- PSNL vs TLSA Comparison
PSNL vs TLSA Comparison
Compare PSNL & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | TLSA |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 729.1M | 155.2M |
| IPO Year | 2019 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PSNL | TLSA |
|---|---|---|
| Price | $6.18 | $1.23 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $12.20 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 132.9K |
| Earning Date | 05-05-2026 | 05-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.58 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $69,648,000.00 | N/A |
| Revenue This Year | $15.47 | N/A |
| Revenue Next Year | $39.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.83 | $0.73 |
| 52 Week High | $11.50 | $2.60 |
Technical Indicators
Market Signals| Indicator | PSNL | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 33.26 | 42.22 |
| Support Level | $4.65 | N/A |
| Resistance Level | $9.64 | $1.51 |
| Average True Range (ATR) | 0.54 | 0.11 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 3.15 | 25.00 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.